As we adjust to the post-COVID environment, hear from industry leaders about the biotech global investment and drug pipeline environment. In addition, we’ll look at why biotech companies are increasingly exploring clinical opportunities in APAC, to achieve FDA accepted data and what actionable strategies can be implemented to leverage APAC’s streamlined regulatory processes and accelerated clinical development. Our Regulatory affairs leaders from North America and Australia will share insight into processes supporting a robust clinical program, and how Phase 1 FDA accepted data from Australia, specifically, can launch global drug development programs.
Click here to find additional details and registration information.
Related Content
Beyond Accelerated Approvals: External Control Arms
Hear this panel's discussion on the strategic use of external control arms and, if done correctly, how they can help bring products to market in a shorter time and for lower costs.
Stay Ahead of the Game: Learn How to Conduct an Evidence-Based GVD Faster and Smarter to Improve Market Access
Hear three experts address systematic literature review issues that can negatively affect your Global Value Dossiers (GVDs) and how automation can improve your product's market access.